½ÃÀ庸°í¼­
»óǰÄÚµå
1764874

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ¿¹Ãø - Áö¿ªº° ºÐ¼® - Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº°(-2031³â)

Asia Pacific Organ Preservation Solution Market Forecast to 2031 - Regional Analysis - by Product, Application, Type, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº 2023³â¿¡ 3,797¸¸ 8,810´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 8,119¸¸ 9,780´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2031³âÀÇ CAGRÀº 10.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

½ÃÀå ÁøÃâ±â¾÷ÀÇ Àü·«Àû ³ë·ÂÀÌ ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀ» µÞ¹Þħ

´Ù¾çÇÑ °³¹ß ±â¾÷ÀÌ ¸¸¼º ÁúȯÀÇ Ä¡·á¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ¼±ÁøÀû Á¦Ç°À» °³¹ßÇϱâ À§ÇØ Á¦Ç°ÀÇ ¹ß¸Å³ª Àü·«Àû Á¦ÈÞ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

2022³â 4¿ù, Æ®·£½º¸Þµñ½º ±×·ìÀº ¼øÈ¯ »çÈÄ ±âÁõÀڷκÎÅÍ Á¶´ÞµÈ Àå±â¸¦ »ç¿ëÇϱâ À§ÇÑ OCS ½ÉÀå ½Ã½ºÅÛÀÇ »ó¾÷¿ë ½ÂÀÎÀ» FDA·ÎºÎÅÍ È¹µæÇÏ¿´½À´Ï´Ù.

2023³â 8¿ù Àå±â À̽ÄÀÇ ÁÖ¿ä ±â¾÷ÀÎ Paragonix Technologies´Â Â÷¼¼´ë °ø¿©ÀÚ Æó º¸Á¸ ½Ã½ºÅÛ BAROguardÀÇ FDA Àΰ¡¸¦ ÃëµæÇß½À´Ï´Ù. ±âÁõÀڷκÎÅÍ ¼ö·ÉÀÚ·Î À̼ÛÇÏ´Â µ¿¾È ±âÁõÀÚÀÇ Æó¿¡ ´ëÇÑ ÃÖÀûÀÇ ¿Âµµ ¹üÀ§¿Í ÀÓ»óÀûÀ¸·Î ±ÇÀåµÇ´Â ÆØÃ¢ ¾Ð·Â ¹üÀ§¸¦ À¯ÁöÇÏ´Â °ÍÀÌ º¸ÀåµË´Ï´Ù.

2024³â 4¿ù, Mayo Clinic°ú Terasaki Institute for Biomedical InnovationÀº Àå±â ÀÌ½Ä °á°ú¸¦ °³¼±Çϱâ À§ÇØ Çù·ÂÇß½À´Ï´Ù. Mayo ClinicÀÇ »ý¹°ÀǷῬ±¸ÀÚ¿Í Terasaki ¿¬±¸¼ÒÀÇ °úÇÐÀÚ´Â Á¦°øµÈ Àå±âÀÇ Á¶´Þ·ÎºÎÅÍ ÀÌ½Ä ¼ö¼ú±îÁöÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú °ÅºÎ ¹ÝÀÀÀÇ À§ÇèÀÌ ³ôÀº ÀÌ½Ä ¼ö·ÉÀÚ¸¦ ƯÁ¤Çϱâ À§ÇÑ ¿¹Ãø ±â¼úÀÇ °³¹ßÀ̶ó´Â µÎ °¡ÁöÀÇ ÁÖ¿ä ¿¬±¸ ºÎ¹®¿¡¼­ Çù·ÂÇÒ ¿¹Á¤ÀÔ´Ï´Ù. À̰ÍÀº ¿¹ÈÄ ¿¹Ãø ½Ã±×´ÏóÀÇ »ý¼º°ú Àå±â À̽Ŀ¡¼­ Ç×ü °³À缺 °ÅºÎ ¹ÝÀÀÀÇ ºÐ¼®À» Æ÷ÇÔÇÕ´Ï´Ù.

µû¶ó¼­ Á¦Ç° ½ÂÀÎ, »ó½Ã ¹× Àü·«Àû Á¦ÈÞÀÇ ±ÞÁõÀº Àå±â º¸Á¸ ¿ë¾× ½ÃÀå¿¡ ¹Ì·¡¿¡ Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ¶ÇÇÑ, °í·ÉÈ­ Àα¸ Áõ°¡, Àå±â ºÎÀüÀ¸·Î À̾îÁö´Â ¸¸¼º ÁúȯÀÇ À¯º´·üÀÇ »ó½Â, Àå±â º¸Á¸ ¿ë¾×ÀÇ °³¹ß ¹× °³·® Áõ°¡¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ÀϺ» ½ÃÀå ¼ºÀåÀº Àå±â À̽ÄÀ» ¿ä±¸ÇÏ´Â ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. Áß±¹ÀÇ 60¼¼ ÀÌ»ó ³ëÀÎ ºñÀ²Àº 2010-2040³â±îÁö 12.4%¿¡¼­ 28%·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼º ºñ°¨¿°¼º Áúȯ(NCDs)À¸·Î º¸°íµÇ¾î ÀÖ½À´Ï´Ù. Áß±¹Àº Àü ¼¼°è ´Ù¸¥ ³ª¶óµéº¸´Ù °£¾Ï ¹ßº´·üÀÌ ´õ ³ô½À´Ï´Ù. Àü ¼¼°è Àα¸ÀÇ 20% ¹Ì¸¸À» Â÷ÁöÇÏÁö¸¸, Áß±¹Àº Àüü ½Å±Ô °£¾Ï ȯÀÚÀÇ °ÅÀÇ Àý¹ÝÀ» Â÷ÁöÇÕ´Ï´Ù. °£¼¼Æ÷¾Ï(HCC)Àº ¿ø¹ß¼º °£¾ÏÀÇ ¾à 90%¸¦ Â÷ÁöÇÕ´Ï´Ù. ÁÖ·Î ¸¸¼º BÇü ¶Ç´Â CÇü °£¿°À¸·Î ÀÎÇÑ °£°æº¯Áõ ¶Ç´Â ÈäÅͰ¡ Àִ ȯÀÚ¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. ´ç´¢º´°ú °£¾Ï°ú °°Àº ¸¸¼º ÁúȯÀº Àå±â ¼Õ»óÀ» ÃÊ·¡ÇÕ´Ï´Ù. µû¶ó¼­ Áß±¹¿¡¼­´Â Àå±â À̽ÄÀÇ Çʿ伺ÀÌ Áõ°¡ÇÏ¿© Àå±â º¸Á¸ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¼öÀͰú 2031³â±îÁöÀÇ ¿¹Ãø(¹ÌÈ­ õ ´Þ·¯)

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°º°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº À§½ºÄܽŠ´ëÇÐ ¼Ö·ç¼Ç, Ä«½ºÅäµð¿Ã HTK, ÆÛÆÄµ¦½º, ÇÏÀÌÆ÷¼­¸ðÁ¹ µîÀ¸·Î ºÐ·ùµË´Ï´Ù.

ÀÀ¿ë ºÐ¾ßº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Á¤Àû ³ÃÀå º¸°ü, Àúü¿Â ±â°è °ü·ù, »ó¿Â ±â°è °ü·ù µîÀ¸·Î ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº ½ÅÀå, °£, Æó, ½ÉÀå µîÀ¸·Î ºÐ·ùµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¼ ¶§ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Àå±â ÀÌ½Ä ¼¾ÅÍ, º´¿ø ¹× Àü¹® Ŭ¸®´ÐÀ¸·Î ºÐ·ùµË´Ï´Ù. Àå±â ÀÌ½Ä ¼¾ÅÍ ºÎ¹®Àº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù.

XVIVO Perfusion, TransMedics, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, Shanghai Genext Pharmaceutical Technology´Â ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀåÀÇ ¸Å·Â

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ÀÇ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀκм®
    • ÆÄ¿îµ¥ÀÌ¼Ç ¼öÄ¡ÀÇ °³¹ß
    • µ¥ÀÌÅÍÀÇ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àå±â ÀÌ½Ä ¿ä±¸ Áõ°¡
    • ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °í¾×ÀÇ Àå±â ÀÌ½Ä ¼ö¼ú
    • Àå±âÀÇ °¡¿ë¼º Á¦ÇÑ
  • ½ÃÀå ±âȸ
    • ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • ÇâÈÄÀÇ µ¿Çâ
    • ±â°è °ü·ù ±â¼ú·ÎÀÇ À̵¿
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦5Àå Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ºÐ¼®

  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀÇ ¼öÀÍ(2021-2031³â)
  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¿¹Ãø ºÐ¼®

Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - Á¦Ç°º°

  • À§½ºÄܽŠ´ëÇÐ ¼Ö·ç¼Ç
  • Ä«½ºÆ®µð¿Ã HTK
  • ÆÄÆÄµ¦½º
  • ÇÏÀÌÆ÷¼­¸ðÁ¹
  • ±âŸ

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - ¿ëµµº°

  • Á¤Àû ³ÃÀå º¸Á¸
  • Àúü¿Â±â°è °ü·ù
  • »ó¿Â±â°è °ü·ù
  • ±âŸ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - À¯Çüº°

  • ½ÅÀå
  • °£
  • Æó
  • ½ÉÀå
  • ±âŸ

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - ÃÖÁ¾ »ç¿ëÀÚº°

  • Àå±â ÀÌ½Ä ¼¾ÅÍ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç Àå±â º¸Á¸ ¿ë¾× ½ÃÀå - ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦11Àå Àå±â º¸Á¸ ¿ë¾× ½ÃÀå - »ê¾÷ Á¤¼¼

  • ¼Ò°³
  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀÇ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • XVIVO Perfusion
  • TransMedics
  • Dr. Franz Koehler Chemie GmbH
  • Accord Healthcare
  • Shanghai Genext Pharmaceutical Technology

Á¦13Àå ºÎ·Ï

SHW 25.07.14

The Asia Pacific organ preservation solution market was valued at US$ 37,978.81 thousand in 2023 and is expected to reach US$ 81,199.78 thousand by 2031; it is estimated to register a CAGR of 10.1% from 2024 to 2031.

Strategic Initiatives by Market Players Fuels Asia Pacific Organ Preservation Solution Market

Various market players focus on product launches or strategic collaborations to develop advanced products that help ease the treatment of chronic disorders. There have been various recent developments, such as product launches, mergers, and acquisitions in recent years.

In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart System for using it with organs procured from donors after circulatory death. The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donors-after-circulatory-death (DCD) hearts.

In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system-BAROguard. The BAROguard system combines Paragonix's advanced hypothermic preservation technology with automated continuous and active airway pressure control. This control ensures the maintenance of optimal temperature range and a clinically recommended inflation pressure range for donor's lungs throughout their transfer from donors to recipients. This novel combination of advanced technologies further reinforces the company's ongoing commitment to improving and redefining the standard of care within the field of transplant medicine.

In April 2024, the Mayo Clinic and the Terasaki Institute for Biomedical Innovation collaborated to improve organ transplant outcomes. Mayo Clinic biomedical researchers and Terasaki Institute scientists plan to collaborate on two main study areas: real-time monitoring of donated organ health from procurement to transplant surgery and the development of predictive technologies to identify transplant recipients with a higher risk of rejection. This will involve creating prognostic signatures and assays for antibody-mediated rejection of organ transplants. The initial projects are expected to be completed within 24-30 months.

Thus, a surge in product approvals, launches, and strategic collaborations is likely to create considerable growth opportunities for the organ preservation solution market in the future.

Asia Pacific Organ Preservation Solution Market Overview

The organ preservation solution market in Asia Pacific is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market growth in the region is attributed to the growing number of organ transplantations across several countries in Asia Pacific, increasing aging population, rising prevalence of chronic diseases that lead to organ failure, and increasing developments and improvements in organ preservation solutions. China is expected to be the largest market for organ preservation solutions in Asia Pacific. The market growth in the country is attributed to the high prevalence of chronic diseases seeking organ transplantation. According to a recent study, "Chronic Illness and Ageing in China," China's population is aging, and chronic illnesses are increasingly prevalent in the country. The proportion of people aged 60 years and above in China is expected to rise from 12.4% to 28% from 2010 to 2040. In China, ~80% of deaths of people aged 60 years are reported due to chronic noncommunicable diseases (NCDs). Chronic obstructive pulmonary disease (COPD), stroke, ischemic heart disease, and type 2 diabetes are among the most prevalent diseases in the country. China has a greater rate of liver cancer than other countries across the world. According to the World Health Organization, ~400,000 people are diagnosed with liver cancer, and around 368,000 people die due to the disease in China every year. Although accounting for less than 20% of the global population, China accounts for nearly half of all new liver cancer cases. Hepatocellular carcinoma (HCC) represents roughly 90 % of all occurrences of primary liver cancer. It develops mainly in those patients with cirrhosis, or scarring, due to chronic hepatitis B or C. Chronic diseases such as diabetes and liver cancer lead to organ damage. Therefore, the need for organ transplants has increased in China, bolstering the demand for organ preservation solutions.

Asia Pacific Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)

Asia Pacific Organ Preservation Solution Market Segmentation

The Asia Pacific organ preservation solution market is categorized into product, application, type, end user, and country.

Based on product, the Asia Pacific organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, HypoThermosol, and others. The University of Wisconsin segment held the largest market share in 2023.

In terms of application, the Asia Pacific organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.

By type, the Asia Pacific organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.

Based on end user, the Asia Pacific organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.

By country, the Asia Pacific organ preservation solution market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific organ preservation solution market share in 2023.

XVIVO Perfusion, TransMedics, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, and Shanghai Genext Pharmaceutical Technology, are among the leading companies operating in the Asia Pacific organ preservation solution market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Organ Preservation Solution Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Need for Organ Transplantation
    • 4.1.2 Increasing Prevalence of Chronic Diseases
  • 4.2 Market Restraints
    • 4.2.1 Expensive Organ Transplant Surgeries
    • 4.2.2 Limited Organ Availability
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Market Players
  • 4.4 Future Trends
    • 4.4.1 Shift Toward Machine Perfusion Technique
  • 4.5 Impact of Drivers and Restraints:

5. Organ Preservation Solution Market - Asia Pacific Analysis

  • 5.1 Organ Preservation Solution Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Organ Preservation Solution Market forecast Analysis

6. Asia Pacific Organ Preservation Solution Market Analysis - by Product

  • 6.1 University of Wisconsin Solution
    • 6.1.1 Overview
    • 6.1.2 University of Wisconsin Solution: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.2 Custodiol HTK
    • 6.2.1 Overview
    • 6.2.2 Custodiol HTK: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.3 Perfadex
    • 6.3.1 Overview
    • 6.3.2 Perfadex: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.4 HypoThermosol
    • 6.4.1 Overview
    • 6.4.2 HypoThermosol: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

7. Asia Pacific Organ Preservation Solution Market Analysis - by Application

  • 7.1 Static Cold Storage
    • 7.1.1 Overview
    • 7.1.2 Static Cold Storage: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.2 Hypothermic Machine Perfusion
    • 7.2.1 Overview
    • 7.2.2 Hypothermic Machine Perfusion: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.3 Normothermic Machine Perfusion
    • 7.3.1 Overview
    • 7.3.2 Normothermic Machine Perfusion: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

8. Asia Pacific Organ Preservation Solution Market Analysis - by Type

  • 8.1 Kidneys
    • 8.1.1 Overview
    • 8.1.2 Kidneys: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.2 Liver
    • 8.2.1 Overview
    • 8.2.2 Liver: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.3 Lungs
    • 8.3.1 Overview
    • 8.3.2 Lungs: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.4 Heart
    • 8.4.1 Overview
    • 8.4.2 Heart: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

9. Asia Pacific Organ Preservation Solution Market Analysis - by End User

  • 9.1 Organ Transplant Centers
    • 9.1.1 Overview
    • 9.1.2 Organ Transplant Centers: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 9.2 Hospitals
    • 9.2.1 Overview
    • 9.2.2 Hospitals: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 9.3 Specialty Clinics
    • 9.3.1 Overview
    • 9.3.2 Specialty Clinics: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

10. Asia Pacific Organ Preservation Solution Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific: Organ Preservation Solution Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 10.1.1.1 Asia Pacific: Organ Preservation Solution Market - Revenue and forecast Analysis - by Country
      • 10.1.1.2 China: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.2.1 China: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.2.2 China: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.2.3 China: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.2.4 China: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.3 Japan: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.3.1 Japan: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.3.2 Japan: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.3.3 Japan: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.3.4 Japan: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.4 India: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.4.1 India: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.4.2 India: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.4.3 India: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.4.4 India: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.5 Australia: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.5.1 Australia: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.5.2 Australia: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.5.3 Australia: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.5.4 Australia: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.6 South Korea: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.6.1 South Korea: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.6.2 South Korea: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.6.3 South Korea: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.6.4 South Korea: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.7 Rest of APAC: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.7.1 Rest of APAC: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.7.2 Rest of APAC: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.7.3 Rest of APAC: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.7.4 Rest of APAC: Organ Preservation Solution Market Breakdown, by End User

11. Organ Preservation Solutions Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Organ Preservation Solutions Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 XVIVO Perfusion
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 TransMedics
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Dr. Franz Koehler Chemie GmbH
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Accord Healthcare
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Shanghai Genext Pharmaceutical Technology
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦